Medical Pharmacology: ANS Cholinergic Pharmacology — Module 3: Tier 3

Medical Pharmacology Question Bank: ANS Cholinergic Pharmacology — Module 3 | Tier 3 — Clinical Vignettes

Chapter 6: Cholinergic Pharmacology — Module 3: Nicotinic Pharmacology — NMJ, Ganglionic, and CNS Drugs
Tier 3 — Advanced Reasoning

1. A 28-year-old man sustained a T4 complete spinal cord injury in a motorcycle accident 6 weeks ago. He is admitted to the surgical ICU with septic shock secondary to a pressure ulcer infection and requires emergency intubation. His serum potassium is 4.8 mEq/L. The trauma surgery resident asks whether succinylcholine from the RSI protocol is safe to use. Which of the following most accurately assesses succinylcholine safety in this patient?

A) Succinylcholine is safe because 6 weeks have elapsed since injury, placing the patient beyond the 4-week peak risk window; serum potassium of 4.8 mEq/L confirms no dangerous baseline hyperkalemia
B) Succinylcholine carries only a mild relative contraindication at this time point; atropine pretreatment will adequately mitigate the risk of succinylcholine-induced bradycardia in the setting of high spinal cord injury
C) Succinylcholine is contraindicated in this patient; extrajunctional nicotinic receptor upregulation peaks within 2–4 weeks of denervation but persists indefinitely as long as the denervation remains established — the serum potassium of 4.8 mEq/L is irrelevant as a safety indicator because the danger is the acute efflux of 5–10 mEq/L triggered by depolarization of the expanded receptor population, not the baseline level; rocuronium 1.2 mg/kg is the correct RSI agent
D) Succinylcholine is contraindicated only when pre-induction serum potassium exceeds 5.5 mEq/L; since this patient's potassium is 4.8 mEq/L, it is acceptable provided the dose is reduced to 0.5 mg/kg to limit the magnitude of endplate depolarization
E) Succinylcholine is safe in chronic spinal cord injury because the initial extrajunctional receptor upregulation undergoes downregulation back to baseline after the first 4–6 weeks as denervated muscle reaches a new homeostatic steady state

ANSWER: C

Rationale:

This question tests two concepts that are commonly confused: the temporal course of extrajunctional receptor upregulation and the irrelevance of baseline serum potassium to the hyperkalemia risk. Regarding the time course: extrajunctional nicotinic receptor upregulation in denervation injury begins within 24–72 hours, peaks at approximately 2–4 weeks, and then plateaus at a persistently elevated level for as long as the denervation or immobilization state persists. In established complete spinal cord injury the denervation is permanent, and extrajunctional receptor upregulation does not regress. The risk therefore does not resolve after 6 weeks — it remains present indefinitely and constitutes an absolute contraindication to succinylcholine throughout the chronic phase of spinal cord injury. Regarding baseline potassium: the danger is not from the resting serum potassium level but from the acute surge generated by simultaneous depolarization of the vastly expanded receptor population. Normal adult skeletal muscle contains nicotinic receptors tightly clustered at the endplate, covering a small fraction of the total sarcolemmal surface. In chronic denervation, extrajunctional fetal-type and alpha-7-containing receptors spread throughout the entire muscle membrane. When succinylcholine depolarizes this expanded surface, the potassium that exits the cell during the prolonged depolarization phase is proportional to receptor density and open channel time, not to the baseline serum level. A rise of 5–10 mEq/L can occur within 2–3 minutes regardless of whether the starting potassium is 3.5 or 4.8 mEq/L. Rocuronium 1.2 mg/kg is the correct RSI agent. Option D creates a fabricated threshold at 5.5 mEq/L and incorrectly implies dose reduction mitigates the mechanism.

Option A: Option A incorrectly implies 6 weeks marks the end of the risk window and incorrectly uses baseline potassium as a safety indicator.
Option B: Option B incorrectly frames the primary risk as bradycardia.
Option E: Option E fabricates a receptor downregulation process that does not occur in established permanent denervation.
Option D: Option D is incorrect: the 5.5 mEq/L threshold for acceptable succinylcholine use is fabricated and not supported by clinical guidelines; the contraindication to succinylcholine in high-risk conditions (spinal cord injury, prolonged immobilization, burns, crush injury, denervation) is not a potassium threshold-based rule but a mechanism-based absolute contraindication — in conditions with extrajunctional nAChR upregulation, succinylcholine can trigger massive potassium efflux from the entire muscle membrane that can cause fatal hyperkalemia at any baseline potassium level; additionally, dose reduction does not mitigate the mechanism of extrajunctional receptor-mediated depolarization.

2. A 19-year-old male with no known medical history undergoes elective shoulder arthroscopy under general anesthesia. Twenty-five minutes after induction with propofol, succinylcholine, and isoflurane, the nurse notes progressive muscle rigidity. Temperature has risen from 36.8 to 39.4 degrees C, end-tidal CO2 has increased from 38 to 72 mmHg despite unchanged ventilator settings, and heart rate is 138 bpm. ABG shows pH 7.18, PaCO2 78 mmHg, lactate 6.2 mmol/L. Which of the following most accurately identifies the diagnosis, molecular mechanism, and correct immediate pharmacological intervention?

A) This represents neuroleptic malignant syndrome triggered by the dopaminergic effects of isoflurane; treatment is bromocriptine and dantrolene
B) This is thyroid storm precipitated by surgical stress; treatment is propylthiouracil, beta-blockade, and glucocorticoids
C) This is serotonin syndrome triggered by an unrecognized drug interaction; treatment is cyproheptadine and benzodiazepines
D) This represents anaphylaxis to succinylcholine manifesting with cardiovascular collapse and bronchospasm; treatment is epinephrine, diphenhydramine, and methylprednisolone
E) This is malignant hyperthermia triggered by succinylcholine and isoflurane; the mechanism is uncontrolled calcium release from the sarcoplasmic reticulum through mutant ryanodine receptor 1 (RYR1) channels producing the hypermetabolic crisis; immediate treatment requires discontinuation of all triggering agents, dantrolene 2.5 mg/kg IV bolus repeated every 5 minutes to a maximum of 10 mg/kg, active cooling, correction of hyperkalemia and acidosis, and continued hemodynamic monitoring

ANSWER: E

Rationale:

This presentation is classic malignant hyperthermia — a pharmacogenetic, life-threatening hypermetabolic crisis of skeletal muscle triggered by volatile halogenated anesthetics and succinylcholine in genetically susceptible individuals. The triad of rapidly rising end-tidal CO2 (the earliest and most sensitive sign), progressive muscle rigidity, and hyperthermia in the context of triggering anesthetic agents is diagnostic until proven otherwise. The profound metabolic acidosis with elevated lactate reflects simultaneous uncontrolled aerobic and anaerobic metabolism driven by the intracellular calcium surge. The molecular mechanism involves mutations most commonly in the RYR1 gene — the ryanodine receptor type 1, which is the calcium release channel of the sarcoplasmic reticulum in skeletal muscle — and less commonly in CACNA1S (calcium voltage-gated channel subunit alpha1 S gene) encoding the dihydropyridine receptor. Mutant RYR1 channels are pathologically sensitive to triggering agents and undergo sustained, unregulated calcium release into the cytoplasm. The resulting calcium surge drives uncontrolled actin-myosin cross-bridge cycling producing rigidity, markedly increases oxidative phosphorylation and anaerobic glycolysis producing CO2, heat and lactate, and activates destructive intracellular cascades. Without treatment, the syndrome progresses to rhabdomyolysis, hyperkalemia, acute kidney injury, disseminated intravascular coagulation, and death. Dantrolene is the specific antidote, binding directly to the RYR1 channel and reducing its probability of pathological opening. The initial dose is 2.5 mg/kg IV bolus repeated every 5 minutes as needed to a maximum of 10 mg/kg, though higher cumulative doses are sometimes required in severe cases. All triggering agents must be discontinued immediately, a clean anesthesia circuit or total IV anesthesia substituted, active cooling initiated, sodium bicarbonate administered for severe acidosis, and hyperkalemia treated aggressively. The MH (malignant hyperthermia) hotline should be contacted for real-time guidance.

Option A: Option A incorrectly identifies neuroleptic malignant syndrome, which is a dopamine-mediated syndrome developing over days in antipsychotic-treated patients — not an acute intraoperative crisis.
Option B: Option B is incorrect — thyroid storm does not produce the muscle rigidity and extreme acute metabolic derangement described.
Option C: Option C describes serotonin syndrome, which lacks profound rigidity and extreme hypercarbia and is not triggered by anesthetic agents alone.
Option D: Option D misidentifies the presentation as anaphylaxis, which presents with cardiovascular collapse and bronchospasm rather than rigidity, hypercarbia, and severe metabolic acidosis.

3. A 54-year-old woman requires emergency RSI for acute respiratory failure. She carries a documented homozygous atypical butyrylcholinesterase (BChE) genotype confirmed by dibucaine number of 22, and previously experienced a 4-hour succinylcholine apnea after an elective procedure. The emergency physician must select a neuromuscular blocking agent. Which of the following is the correct agent selection and management rationale?

A) Rocuronium 1.2 mg/kg is the correct RSI agent; succinylcholine is absolutely contraindicated because homozygous atypical BChE cannot hydrolyze succinylcholine at a clinically meaningful rate, producing prolonged paralysis of unpredictable duration as documented by her prior 4-hour apnea; rocuronium achieves RSI-equivalent onset and can be completely reversed at any depth by sugammadex 16 mg/kg, making this the safest approach; mivacurium is also contraindicated as it too is BChE-dependent
B) Mivacurium is the preferred agent because it is short-acting with the fastest spontaneous recovery of any nondepolarizing NMB, providing RSI-comparable intubating conditions with minimal risk of prolonged block
C) Succinylcholine can be used in BChE deficiency provided the dose is reduced to 0.1 mg/kg, as the lower total drug burden keeps duration within acceptable clinical limits
D) Vecuronium 0.1 mg/kg is the preferred RSI agent in BChE deficiency because it undergoes entirely hepatic metabolism and its intermediate duration of 25–40 minutes is well-matched to RSI requirements
E) Succinylcholine remains the preferred RSI agent even in homozygous BChE deficiency because its onset advantage outweighs the risk of prolonged block, and neostigmine can be given at the end of the procedure to reverse residual succinylcholine effect

ANSWER: A

Rationale:

This patient's documented homozygous atypical BChE genotype (dibucaine number 22, compared with normal 70–85) with a prior 4-hour succinylcholine apnea establishes an absolute contraindication to succinylcholine. Butyrylcholinesterase is the sole enzyme responsible for succinylcholine hydrolysis in plasma. In homozygous atypical BChE, the enzyme has markedly reduced affinity for succinylcholine, and the drug is metabolized at an extremely slow rate — extending block from the normal 8–12 minutes to 2–6 hours or longer. A prior documented 4-hour apnea confirms the clinical severity of this patient's deficiency. Rocuronium 1.2 mg/kg is the correct RSI alternative. At this dose, onset is 60–75 seconds and intubating conditions are excellent. Critically, rocuronium is metabolized entirely by the liver and excreted through biliary and renal routes with no BChE dependence. Should intubation fail or immediate return of neuromuscular function be required, sugammadex 16 mg/kg reverses even profound rocuronium block within 3 minutes — providing a reliable exit strategy that does not exist with succinylcholine. This is the clinical scenario in which rocuronium plus sugammadex most clearly demonstrates superiority over succinylcholine. An important corollary: mivacurium is also contraindicated in this patient because mivacurium is also metabolized exclusively by BChE. A patient with homozygous atypical BChE who receives mivacurium will experience the same prolonged block seen with succinylcholine. This point is frequently overlooked in clinical practice.

Option B: Option B is incorrect — mivacurium is BChE-dependent and contraindicated in this patient.
Option C: Option C is incorrect — dose reduction does not alter the kinetics of an enzymatically deficient system; the drug simply accumulates for longer at any dose.
Option D: Option D is incorrect — vecuronium 0.1 mg/kg has an onset of 3–5 minutes, which is incompatible with RSI requirements.
Option E: Option E is incorrect — prior documented prolonged apnea is itself the contraindication, and neostigmine has no mechanism to reverse succinylcholine block or restore BChE activity.

4. A 72-year-old woman with obesity (BMI 38 kg/m2) and COPD undergoes elective right hemicolectomy under general anesthesia with rocuronium. At the end of the procedure, neostigmine 2.5 mg with glycopyrrolate 0.5 mg is administered when the TOF count reaches 3 with visible fade. She is extubated and transferred to the PACU. Twenty-five minutes later she develops inspiratory stridor, progressive oxygen desaturation to 88% on 6 L/min nasal cannula, and difficulty swallowing. Mental status is intact and she is anxious but following commands. Which of the following most accurately identifies the cause and correct management?

A) The patient has developed an acute COPD exacerbation triggered by surgical stress; nebulized bronchodilators, systemic corticosteroids, and noninvasive positive pressure ventilation should be initiated
B) The patient is experiencing opioid-induced respiratory depression; naloxone 0.4 mg IV should be administered and repeated every 2 minutes as needed
C) The patient has developed a pulmonary embolism; CT pulmonary angiography should be obtained urgently and anticoagulation initiated
D) This is most likely residual neuromuscular blockade; neostigmine was administered at TOF count of 3 with visible fade — a suboptimal reversal point below the threshold for reliable neostigmine efficacy — and the combination of obesity and COPD severely limits the respiratory and pharyngeal reserve needed to compensate for any residual weakness; sugammadex should be administered at 2 mg/kg (or 4 mg/kg if quantitative monitoring now shows deep block), airway support provided simultaneously, and quantitative TOF confirmation of ratio at least 0.9 obtained before reducing respiratory support
E) This is laryngospasm secondary to residual secretions at the vocal cords; jaw thrust, positive pressure ventilation, and succinylcholine 0.5 mg/kg for refractory laryngospasm are the correct interventions

ANSWER: D

Rationale:

This PACU presentation — inspiratory stridor, desaturation, dysphagia, and anxiety with intact cognition appearing 25 minutes after extubation — is highly characteristic of residual neuromuscular blockade. The symptom constellation reflects impairment of upper airway and pharyngeal muscles, which are disproportionately sensitive to residual NMB compared with the adductor pollicis used for monitoring, and which have a higher safety factor requirement than the limb muscles used to assess clinical strength. The neostigmine was administered at a suboptimal reversal point. Guidelines recommend neostigmine reversal when TOF count is at least 4, ideally with a detectable TOF ratio approaching 0.4 or higher. At TOF count of 3 with visible fade, the block was deeper than the threshold for reliable neostigmine efficacy, and the dose of 2.5 mg may have been insufficient for the residual block present. This produces a recognized clinical pattern: partial and apparently successful neostigmine reversal followed by re-emergence of pharyngeal and upper airway weakness in the PACU as residual NMB outlasts the neostigmine effect. Two patient-specific factors amplify the risk substantially. Obesity reduces functional residual capacity and increases the work of breathing, meaning any degree of respiratory muscle weakness has disproportionate ventilatory impact. COPD limits the respiratory reserve needed to compensate for impaired diaphragmatic function. Together, these conditions lower the threshold at which residual NMB produces clinically significant respiratory compromise. Sugammadex is the definitive treatment. If quantitative TOF monitoring shows moderate block (TOF ratio detectable but less than 0.9), sugammadex 2 mg/kg is appropriate. If deep block is present (TOF count 1–2 or PTC present without TOF response), sugammadex 4 mg/kg should be used. Airway support must accompany pharmacological reversal, and reintubation equipment should be immediately available.

Option A: Option A is incorrect — COPD exacerbation does not cause stridor or dysphagia acutely in this context.
Option B: Option B is incorrect — opioid-induced respiratory depression causes decreased consciousness and bradypnea, not stridor and dysphagia with intact cognition.
Option C: Option C is incorrect — pulmonary embolism does not produce stridor or dysphagia and would present with hypoxemia plus pleuritic pain, tachycardia, or hemodynamic compromise.
Option E: Option E is incorrect — while laryngospasm should be in the differential for PACU stridor, the dysphagia, progressive course at 25 minutes post-extubation, and reversal context make residual NMB far more likely; administering succinylcholine without confirming the true cause would also risk hyperkalemia in this elderly patient.

5. A 41-year-old woman with bipolar I disorder, stable on lithium and quetiapine for 18 months with no hospitalizations or mood episodes in the past year, requests smoking cessation pharmacotherapy. She smokes 25 cigarettes per day and has failed two prior attempts with nicotine patch monotherapy. She is asking specifically about varenicline. Her psychiatrist has confirmed stable remission and is supportive of a cessation attempt. Which of the following most accurately characterizes the risk-benefit analysis and appropriate management of varenicline in this patient?

A) Varenicline is absolutely contraindicated in any patient with a documented psychiatric diagnosis; the only safe options are continued nicotine replacement therapy with combination patch and rescue form
B) Varenicline is appropriate for this patient given her stable psychiatric status; the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial — a large randomized study of smokers with and without psychiatric disorders — demonstrated that varenicline did not significantly increase serious neuropsychiatric adverse events compared with placebo, NRT, or bupropion even in patients with bipolar disorder and other major psychiatric conditions; varenicline should be started with baseline mood monitoring, the patient counseled to report any mood changes promptly, and coordination maintained with her psychiatrist throughout
C) Varenicline should be deferred until bupropion has been tried, as bupropion is required as the mandatory second-line agent before varenicline is considered in any patient with a psychiatric history
D) Varenicline should be avoided indefinitely because lithium and varenicline have a pharmacokinetic interaction — varenicline inhibits renal lithium tubular secretion, increasing lithium levels to potentially toxic concentrations
E) Varenicline can be prescribed but with caution, because the EAGLES trial demonstrated that varenicline produces significantly higher rates of serious neuropsychiatric adverse events than placebo specifically in patients with bipolar disorder, and mandatory monthly psychiatric evaluation is required by the prescribing label

ANSWER: B

Rationale:

The management of smoking cessation in patients with stable psychiatric disorders underwent a significant evidence-based revision following publication of the EAGLES trial (Anthenelli et al., 2016, Lancet). This large, randomized, double-blind, triple-dummy trial enrolled over 8,000 smokers with and without established psychiatric diagnoses including major depressive disorder, bipolar disorder, schizophrenia, and schizoaffective disorder, and compared varenicline, bupropion, NRT patch, and placebo for safety and efficacy. The primary safety outcome was a composite of neuropsychiatric adverse events. The key finding was that varenicline did not significantly increase the incidence of serious neuropsychiatric adverse events compared with placebo, NRT, or bupropion in the psychiatric cohort — including the bipolar disorder subgroup. Varenicline did produce higher rates of nausea (a known side effect) but not of suicidality, aggression, depression, mania, or psychosis. Varenicline also demonstrated superior efficacy for abstinence in both psychiatric and non-psychiatric cohorts. On the basis of this trial, the FDA removed the black box warning for neuropsychiatric adverse effects from the varenicline label in December 2016. For this patient specifically — stable bipolar I disorder in confirmed remission for 18 months, with psychiatrist involvement — the evidence supports offering varenicline as the most effective pharmacological cessation agent. The practical approach includes establishing a baseline mood assessment, counseling the patient on early warning signs of mood change, scheduling follow-up contact within 1–2 weeks of initiation, and maintaining active communication with her psychiatrist. There is no clinically significant pharmacokinetic interaction between varenicline and lithium. Varenicline is renally excreted unchanged and does not inhibit or induce cytochrome P450 enzymes or renal transporters involved in lithium handling. Option E directly inverts the EAGLES finding; the trial showed no significant increase in neuropsychiatric adverse events in bipolar patients.

Option A: Option A is incorrect — the EAGLES trial specifically refutes an absolute contraindication in stable psychiatric disorders.
Option C: Option C is incorrect — there is no evidence-based requirement to use bupropion before varenicline in psychiatric patients; varenicline has superior efficacy.
Option D: Option D is incorrect — no clinically meaningful pharmacokinetic interaction between varenicline and lithium exists.
Option E: Option E is incorrect: varenicline does not produce significantly higher rates of serious neuropsychiatric adverse events compared to placebo in patients with psychiatric disorders; this statement directly contradicts the EAGLES trial findings; the EAGLES trial specifically demonstrated that varenicline did NOT significantly increase neuropsychiatric adverse events compared to nicotine patch or placebo, even in patients with stable psychiatric disorders (including schizophrenia, bipolar disorder, and MDD); this was a landmark finding that led to removal of the FDA black box warning for serious neuropsychiatric events from varenicline's label; prescribing varenicline with caution and monitoring is appropriate, but stating that EAGLES "demonstrated significantly higher rates" inverts the actual trial finding.

6. A 62-year-old woman presents with a 4-month history of proximal leg weakness that is notably worse when she first attempts to stand or climb stairs but improves substantially after 5–10 minutes of walking. She also notes reduced saliva production and constipation for the past 3 months. Neurological examination shows proximal lower extremity weakness graded 3 out of 5, preserved facial and extraocular muscle strength, and depressed patellar and Achilles reflexes. After 10 seconds of maximal voluntary quadriceps contraction, her patellar reflex becomes brisk. EMG is performed with repetitive nerve stimulation at 3 Hz and at 50 Hz. At 3 Hz, there is a 12% decrement in CMAP (compound muscle action potential) amplitude. At 50 Hz, there is a 320% increment in CMAP amplitude. Which of the following most accurately interprets the electrophysiological findings and their mechanistic significance, and identifies the most appropriate initial pharmacological intervention?

A) The 12% decrement at 3 Hz is the primary diagnostic finding confirming myasthenia gravis; the 320% increment at 50 Hz is an artifact of electrode movement during high-frequency stimulation; treatment with pyridostigmine and thymectomy referral is indicated
B) Both the decrement at 3 Hz and the increment at 50 Hz are non-specific findings in this age group and require muscle biopsy before any pharmacological treatment is initiated
C) The combination of a modest decrement at low-frequency stimulation and a large increment at high-frequency stimulation is the characteristic dual electrophysiological signature of Lambert-Eaton myasthenic syndrome; at rest, acetylcholine release is insufficient to reliably trigger action potentials at all endplates (producing the low-frequency decrement), while high-frequency stimulation causes progressive calcium accumulation that increasingly facilitates release (producing the large increment); the autonomic features (xerostomia, constipation) and exercise-induced improvement confirm presynaptic localization; amifampridine is the appropriate initial pharmacological treatment
D) The 320% increment at 50 Hz indicates a motor neuron disease with fasciculation potentials; the small decrement at 3 Hz reflects early denervation; treatment with riluzole is indicated
E) The findings are consistent with mitochondrial myopathy; the decrement and increment pattern reflects impaired ATP production causing variable neuromuscular transmission; treatment with coenzyme Q10 supplementation is recommended

ANSWER: C

Rationale:

The electrophysiological profile described — modest decrement at low-frequency RNS (3 Hz) with a large increment at high-frequency RNS (50 Hz) — is the characteristic dual finding of Lambert-Eaton myasthenic syndrome and is mechanistically explicable from the presynaptic VGCC (voltage-gated calcium channel) pathophysiology. At rest and with low-frequency stimulation (3 Hz), the impaired calcium entry per action potential (caused by P/Q-type VGCC autoantibody blockade) results in insufficient acetylcholine release to reliably depolarize all endplates to threshold. As the nerve continues to fire at 3 Hz, calcium does not accumulate significantly between stimuli (the interval is too long), and the already-subthreshold release may decline slightly with successive stimuli, producing a modest decrement. This contrasts with myasthenia gravis, which typically produces a larger decrement (15–30%) at 3 Hz due to postsynaptic receptor loss reducing the margin of safety. At high-frequency stimulation (50 Hz), intracellular calcium progressively accumulates in the presynaptic terminal because the inter-stimulus interval (20 ms) is short relative to calcium clearance mechanisms. Each successive stimulus therefore enters a terminal with progressively higher residual calcium, augmenting vesicle fusion and acetylcholine release. The CMAP amplitude progressively increases — the increment — as more endplates are recruited above threshold. An increment exceeding 100% is considered the diagnostic criterion for LEMS (Lambert-Eaton myasthenic syndrome), and values of 200–400% are typical. This increment directly explains the clinical phenomenon of strength improving with sustained exercise. The autonomic features — xerostomia and constipation — confirm that the P/Q-type VGCC autoantibodies are impairing calcium entry not only at the NMJ but also at autonomic nerve terminals mediating salivary and gastrointestinal parasympathetic function. The post-tetanic reflex facilitation on examination (brisk reflex after voluntary contraction) is the bedside correlate of the electrophysiological increment. Amifampridine (3,4-diaminopyridine) is the appropriate initial pharmacological treatment. By blocking presynaptic potassium channels and prolonging action potential duration, amifampridine increases calcium entry per stimulus, compensating for the VGCC antibody-mediated deficit and enhancing acetylcholine release.

Option A: Option A incorrectly interprets the 3 Hz decrement as confirming MG and dismisses the increment as artifact; the increment is real, reproducible, and diagnostically definitive for LEMS.
Option B: Option B incorrectly suggests the findings are nonspecific; the combined decrement-plus-increment pattern is highly specific for LEMS.
Option D: Option D incorrectly attributes the findings to motor neuron disease; the pattern described is not seen in ALS or other motor neuron diseases.
Option E: Option E fabricates a mitochondrial myopathy interpretation; mitochondrial disease does not produce the characteristic decrement-increment pattern.